Pfizer CFO Dave Denton to Depart; Cecile Guegan Named Interim CFO

summarizeSummary

Pfizer announced that CFO Dave Denton will step down in August for an external opportunity, with long-time finance executive Cecile Guegan appointed as interim Chief Financial Officer.

check_boxKey Events · Executive and Board Changes · PFE

• Chief Financial Officer Departure

  Dave Denton will step down from his position as Chief Financial Officer of Pfizer Inc. effective August 15, 2026.

• Reason for Departure

  Mr. Denton is leaving for a professional opportunity outside of the pharmaceutical industry in consumer goods, and his departure is not related to the company's financial results or any disagreements.

• Interim CFO Appointment

  Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026.

• Succession Plan

  Pfizer will conduct a comprehensive internal and external search to identify Mr. Denton's permanent successor.

auto_awesomeAnalysis · PFE · Life Sciences

The departure of a Chief Financial Officer, even for personal career reasons, introduces a period of transition for a company of Pfizer's size. However, the company has mitigated potential disruption by appointing an experienced internal leader, Cecile Guegan, as interim CFO. Ms. Guegan has over two decades of experience within Pfizer's finance organization, including leadership roles in the global biopharmaceutical business and involvement in major integrations like Seagen. The explicit statement that the departure is not related to Pfizer's financial performance or any disagreements helps to alleviate immediate concerns about the company's stability.